Brain Advance Access originally published online on July 7, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brain, Vol. 126, No. 9, 1940-1954,
September 2003
© 2003 Guarantors of Brain
doi: 10.1093/brain/awg197
Prognosis of vertebrobasilar transient ischaemic attack and minor stroke
Stroke Prevention Research Unit, University Department of Clinical Neurology, Radcliffe Infirmary, Oxford, UK
Correspondence to: Dr P. M. Rothwell, Stroke Prevention Research Unit, Department of Clinical Neurology, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK E-mail: peter.rothwell{at}clneuro.ox.ac.uk
Received April 3, 2003. Revised April 7, 2003. Accepted April 7, 2003.
 |
Summary |
|---|
 Top Summary IntroductionMaterial and methodsResultsDiscussionReferences |
|---|
Vertebrobasilar (VB) territory transient ischaemic attacks (TIAs) and minor strokes are perceived to have a better prognosis than carotid territory events, and are sometimes managed less aggressively. However, this notion stems mainly from a few small studies in the 1960s and 1970s, and has not been systematically tested. We therefore identified all published studies of prognosis after TIA or minor stroke using MEDLINE and EMBASE, and hand-searching reference lists and relevant journals. In addition, we attempted to include all available individual patient data (IPD) from studies that had not published outcome data by territory of presenting event. Odds of recurrent events were calculated within studies and combined by fixed-effects meta-analysis. Heterogeneity between studies was calculated using the
2 method. We stratified the analysis by time interval between presenting event and inclusion in study, and by study setting (population-based, published hospital-based and unpublished hospital-based). Public ation bias was tested for by linear regression of the standard normal deviate against precision. Eight hundred and twenty abstracts were reviewed, and 304 papers were considered in detail. Of these, 43 studies representing 36 independent cohorts (12 196 patients) reported outcomes by territory of presenting event. IPD from five studies (4643 patients) were also included. The following results compare relative risks of VB with carotid events. Studies including the acute phase (up to 7 days) after the presenting event found a higher relative risk of subsequent stroke in patients with VB events [odds ratio (OR) 1.47, 95% confidence interval (CI) 1.1–2.0, P = 0.014]. Conversely, studies mainly recruiting after the acute phase found a lower relative risk (OR 0.74, 95% CI 0.7–0.8, P = 0.00001). In published hospital-based studies, the risk of recurrent stroke was lower for patients presenting with VB events (OR 0.68, 95% CI 0.6–0.8, P < 0.00001). However, there was no difference in hospital-based IPD (OR 1.02, 95% CI 0.8–1.3, P = 0.91). Moreover, in population-based studies, patients with VB events had a higher risk of stroke (OR 1.48, 95% CI 1.1–2.0, P = 0.025). There was no within-stratum heterogeneity. There was no difference in the risk of fatal stroke (OR 1.04, 95% CI 0.8–1.4, P = 0.90). Therefore, we found no evidence that patients presenting with VB events have a lower risk of subsequent stroke or death compared with patients presenting with carotid TIA or minor stroke. Indeed, their risk of stroke is probably higher in the acute phase. Patients with VB events require active preventive treatment. Keywords: cerebral ischaemia; posterior circulation; transient; vertebrobasilar; prognosis
Abbreviations: IPD = individual patient data; TIA = transient ischaemic attack; VB = vertebrobasilar
|
Introduction |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionReferences |
|---|
Patients presenting with transient ischaemic attack (TIA) or minor stroke are at high risk of major vascular events. Five year risks of stroke, coronary events and death vary from 8 to 30%, 12 to 20% and 8 to 37%, respectively, and 57–79% of deaths are vascular (Whisnant et al., 1973
; Simonsen et al., 1981; Muuronen and Kaste, 1982; Heyman et al., 1984a; Howard et al., 1987; Whisnant and Wiebers, 1987; Sørensen et al., 1989; Dennis et al., 1990b; Larsen et al., 1990). However, not all TIAs and minor strokes have the same prognosis. For example, amaurosis fugax is consistently associated with a lower risk of subsequent stroke than carotid territory TIAs (Dennis et al., 1989; Hankey et al., 1991, 1992; Dutch TIA Trial Study Group, 1993; Streifler et al., 1995; Benavente et al., 2001). Such differences in prognosis may influence treatment decisions, and it is important that they are determined reliably.
Vertebrobasilar (VB) territory events account for about 30% of all TIAs and minor strokes. In contrast to carotid events, where research has been stimulated by the development of carotid endarterectomy, there has been relatively little systematic research into the prognosis and risk factors for recurrent vascular events specifically in patients with VB territory TIAs and minor strokes. Despite this, there is a widely held view that VB territory events have a more benign prognosis than carotid territory events (McDowell et al., 1961; Bradshaw and McQuaid, 1963; Marshall, 1964; Baker et al., 1968; Ziegler and Hassanein, 1973; Olsson et al., 1976; Heyman et al., 1984b; Turney et al., 1984; Sivenius et al., 1991; Mohr et al., 1992; Caplan, 1996). This idea stems from the results of a small number of early cohort studies performed in the 1960s and 1970s (Bradshaw and McQuaid, 1963; Marshall, 1964; Acheson, 1971; Baker, 1971; Olsson et al., 1976), many of which do not satisfy modern methodological standards (Kernan et al., 1991). However, partly as a consequence of these early studies, patients with VB events are often investigated less rigorously than patients with carotid events (Caplan, 2000; Culebras et al., 1997) and may not always receive as aggressive preventive treatment against future vascular events (Caplan, 1996; Martin, 1998).
To determine whether or not the prognosis of VB territory TIAs and minor strokes does differ from that of carotid territory events, we reviewed all published studies which reported outcome events according to the vascular territory of the presenting event and included all available individual patient data (IPD) from studies that had not published outcome data by territory of presenting event, and determined the odds of recurrent TIAs, strokes and death.
|
Material and methods |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionReferences |
|---|
Search strategy
We aimed to identify articles which reported follow up data on patients presenting with TIA or minor stroke and which reported these separately for patients presenting with VB and carotid events. Studies were identified by a single observer from MEDLINE®+ and EMBASE® (Silverplatter Winspirs 4.0 on-line and Entrez-PubMed NIH August 5, 2001 for the period 1966 to week 1 August 2001) with the search terms: [posterior circulation OR vertebrobasilar] AND [stroke OR CVA OR TIA OR cerebrovascular OR transient isch(a)emic], and TIA AND [natural history OR prognosis]. The search was limited to human studies only. No restriction was made on the language of publication. Journals that yielded more than 10% of all studies identified electronically were systematically hand-searched for further relevant studies. The reference lists of all papers that met the inclusion criteria were also searched. By contact with principal investigators we attempted to obtain all available IPD from cohort studies containing outcome events for patients with both carotid and VB events that had previously not published outcome data by vascular territory of the presenting event.
Inclusion criteria
Articles were included in the review if they fulfilled the following criteria: (i) prospective or retrospective cohort study; (ii) included patients with TIA, reversible ischaemic attack, reversible ischaemic neurological deficit or minor stroke (defined as reversible, non-disabling, Rankin scale grade not worse than 3, or similar) in VB and carotid territories; (iii) presenting events and outcome data reported separately according to the vascular territory of presenting event; (iv) outcome data reported for one or more of the following: recurrent TIA, stroke (all strokes, major stroke or fatal stroke), myocardial infarction, vascular death or overall mortality.
Data extraction
The following information was extracted from eligible reports:
(i) Aims of study. (ii) Type of study (cohort study, non-randomized treatment trial, randomized controlled trial). (iii) Setting of the study (population-based, hospital-based). (iv) Inclusion and exclusion criteria, and number of excluded patients. (v) Basic demographic data for patients with events in different vascular territories. (vi) Criteria used to determine the vascular territory of the qualifying event. (vii) Time interval between qualifying event and inclusion in study. Studies were grouped into studies including the acute phase, studies recruiting mainly during the subacute phase and studies recruiting mainly during the chronic phase if the majority of patients were enrolled within 7 days, >7 days but <1 month, and >1 month, respectively, after the qualifying event. If this was not stated or not implicit in the study methods it was considered as unknown. (viii) Baseline investigations performed. (ix) Method and frequency of follow up. (x) Length of follow-up and numbers of patients lost to follow up. (xi) Number of patients presenting with TIA or minor stroke (numbers were recorded separately if possible), and number of patients with events in the carotid, VB, both or uncertain territories. (xii) Number of patients with one or more outcome events according to the territory of the qualifying event. Where analyses were reported for more than one period of follow-up, the longest follow up period was used for analysis. Only ischaemic strokes were counted as outcome events if the study discriminated between ischaemic and haemorrhagic strokes. Where possible, numbers of events were extracted from survival curves if no actual numbers were given in the text.
Analysis
Odds of recurrent events in relation to the territory of the presenting event were calculated within individual studies. Where appropriate, odds ratios (ORs) from separate studies were combined by fixed-effects meta-analysis according to the Mantel–Haenszel method. Heterogeneity between estimates from individual studies was calculated using the 2 method. Proportional hazards were assumed. Publication bias was tested for by linear regression of the standard normal deviate against precision (Egger et al., 1997). The characteristics of studies that mainly accounted for heterogeneity were identified by stepwise weighted (by total number of events) linear regression of the natural logarithm of the OR versus year of publication, study setting, length of follow-up, prospective/retrospective design, type of study, time from event until enrolment, and use of strict criteria for diagnosis of VB events. Our analysis was then stratified by the main determinants of heterogeneity. For graphical representation and confidence interval (CI) estimation, 0.5 was added to all four cells in the 2 x 2 table according to established practice where there was no outcome event in one of the cells (Sterne et al., 2001). Duplicate publications on the same cohort and overlapping cohorts were identified to avoid multiple inclusion of patients.
|
Results |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionReferences |
|---|
The electronic literature search identified 2687 publications with the search terms [posterior circulation OR vertebrobasilar] AND [stroke OR CVA OR TIA OR cerebrovascular OR transient isch(a)emic], and 1051 publications with the search terms TIA AND [natural history OR prognosis]. Duplicate records were removed. After exclusion of publications that were clearly not relevant, 820 publications were reviewed and 66 potentially eligible publications identified. Review of reference lists of these papers identified a further 236 potentially eligible reports. Two further studies were identified by hand-searching the journal Stroke, which was the only journal meeting the criterion for hand-searching. A total of 304 papers were considered in detail. Of these, 278 were published in English, nine in German, seven in French, five in Spanish, and one each in Italian, Romanian, Dutch, Japanese and Polish.
A total of 56 articles satisfied our inclusion criteria. Of these, 13 were excluded from the analysis either because they reported only qualitative or quantitative relative risks of outcomes for patients with carotid versus VB events (i.e. no absolute numbers of events were given) (Canadian Cooperative Study Group, 1978; Gent et al., 1980; Candelise et al., 1982; Heyman et al., 1982; Whisnant and Wiebers, 1987; Lee et al., 1990; Carolei et al., 1992; Puranen et al., 1998; Marini et al., 1999), or because they reported only combined outcomes (e.g. stroke and TIA; or stroke and death) (Sørensen et al., 1983, 1989; Matias-Guiu et al., 1987; ESPS Group, 1990). Thus, 43 papers reporting data from 36 independent cohorts were included in the analysis.
We were able to obtain IPD from seven studies including 8447 patients containing outcome data for patients presenting with carotid or VB TIA or minor stroke, five of which, including 4643 patients, had not previously published data on the prognosis according to the vascular territory of the qualifying event (Dennis et al., 1989; Farrell et al., 1991; Hankey et al., 1991; Davenport et al., 1996; Mead et al., 2002; Coull et al., 2003). Two studies had previously published data on the risk of stroke for carotid and VB territory events separately, but they had not published data on the risk of fatal stroke and overall death (Candelise et al., 1986; Dutch TIA Trial Study Group, 1993).
Table 1 summarizes the important characteristics of the eligible reports. Seven papers reported data from five independent population-based studies. The remainder were hospital- and/or office-based. Thirty-one papers reported data from 26 independent prospective cohort studies or treatment trials, and 13 papers reported data from 10 independent retrospective cohort studies. Only six studies specifically intended to determine the prognosis according to the vascular territory of the qualifying event as one of their primary aims (David and Heyman, 1960; Drake and Drake, 1968; Acheson, 1971; Whisnant et al., 1978; Heyman et al., 1984b; Howard et al., 1987), two of which only reported the prognosis for overall mortality. Nine papers reporting data from six independent cohorts reported outcomes for individual patients who had events in both carotid and VB territories (Baker et al., 1968; Drake and Drake, 1968; Friedman et al., 1969; Ziegler and Hassanein, 1973; Cartlidge et al., 1977; Whisnant et al., 1978; Fieschi et al., 1981; Candelise et al., 1986; Keith et al., 1987). Table 2 summarizes which papers reported each specific outcome.
|
|
Risk of stroke
A total of 32 independent studies reported the number of strokes on follow-up. Of these, 16 studies reported ischaemic strokes separately. Fatal strokes were reported for six cohorts. All IPD included data on follow-up strokes and fatal strokes, and all except the Italian Multicenter Study discriminated between ischaemic and haemorrhagic strokes.
There was significant heterogeneity between studies in the odds of subsequent stroke (P = 0.02). Time from event until enrolment and study setting were both significantly associated with the relative risk of stroke and therefore accounted for some of this heterogeneity (P = 0.002 and 0.005, respectively, in the model including one predicting variable). When both variables were tested together, only time from event remained significant (P = 0.027), whereas study setting did not (P = 0.090).
We therefore stratified the analysis first into studies that included the acute phase, studies that mainly recruited during the subacute phase, and studies that mainly recruited during the chronic phase, and secondly, into hospital- versus population-based studies, and substratified hospital-based studies into unpublished IPD versus published studies without calculating an overall OR estimate. There was no evidence of heterogeneity within the resulting strata (P = 0.38 for studies including the acute phase; P = 0.55 for studies mainly recruiting during the sub-acute phase; P = 0.29 for studies mainly recruiting during the chronic phase; P = 0.47 for published hospital-based studies; P = 0.84 for unpublished hospital-based studies; P = 0.54 for population-based studies) The distribution of a plot of ORs of stroke risk for VB versus carotid events against the variance of the OR in each study was symmetrical, and there was no evidence of overall publication bias on regression analysis (P = 0.79). The proportional hazard assumption appeared valid with no correlation between the OR and the mean length of follow up in each study (r = 0.099, P = 0.578).
Patients presenting with VB events had a higher risk for subsequent strokes in studies including the acute phase compared with patients presenting with carotid events (OR 1.47, 95% CI 1.1–2.0, P = 0.014; 1543 patients). In studies mainly recruiting after the acute phase however, patients with VB events had a lower risk of subsequent stroke (OR 0.81, 95% CI 0.6–1.0, P = 0.077; 6752 patients) for studies recruiting mainly during the subacute phase and (OR 0.75, 95% CI 0.6–0.9, P = 0.00026; 8252 patients) for studies recruiting mainly during the chronic phase (Fig. 1).
|
In published hospital-based studies, patients presenting with VB events had a lower risk of subsequent stroke (OR 0.69, 95% CI 0.6–0.8, P < 0.00001, 27 studies; 11 664 patients) than patients presenting with carotid events. In previously unpublished hospital-based IPD, however, there was no difference in the subsequent risk of stroke between carotid and VB events (OR 1.02, 95% CI 0.8–1.3, P = 0.91; three studies, 4149 patients). Moreover, in population-based studies patients with VB events had a higher risk of subsequent stroke compared with patients with carotid events (OR 1.48, 95% CI 1.1–2.0, P = 0.025; seven studies, 1026 patients) (Fig. 2).
|
The lower risk of stroke in patients presenting with VB events in the published hospital-based studies was independent of the diagnostic criteria used for defining the territory of the presenting event: 15 studies used strict ‘Ad Hoc Committee National Institute of Neurological and Communicative Disorders and Stroke (1975)
’ or similar criteria (OR 0.65, 95% CI 0.5–0.8, P = 0.00003, heterogeneity P = 0.21) versus 12 studies with less strict criteria (OR 0.72, 95% CI 0.6–0.9, P = 0.003, heterogeneity P = 0.56). There was no significant difference between studies published before 1980 (OR 0.65, 95% CI 0.5–0.9, P = 0.04, heterogeneity P = 0.09; seven studies) and studies published after 1980 (OR 0.69, 95% CI 0.6–0.8, P < 0.00001, heterogeneity P = 0.59; 20 studies). The findings in the three largest studies (OR 0.66, 95% CI 0.5–0.8, P = 0.00003, heterogeneity P = 0.23) (ESPS Group, 1990; Sivenius et al., 1991; Grotta et al., 1992; Cillessen et al., 1993) did not differ from the remainder (OR 0.71, 95% CI 0.6–0.9, P = 0.003, heterogeneity P = 0.45), and the results were also consistent when the analysis was confined to patients presenting with TIAs only (OR 0.68, 95% CI 0.5–0.8, P = 0.004, heterogeneity P = 0.13; 18 studies).
Studies specifically intending to investigate differences between carotid and VB events found no difference in the risk of subsequent stroke between the vascular territories (OR 1.02, 95% CI 0.7–1.4, P = 0.99, heterogeneity P = 0.04; four studies). There was no difference in the ratio of subsequent disabling strokes versus all strokes between patients initially presenting with VB versus carotid events (OR 0.8, 95% CI 0.6–1.2, P = 0.41, heterogeneity P = 0.37; six cohorts) (Baker et al., 1968; Dennis et al., 1989; Dutch TIA Trial Study Group, 1991; Farrell et al., 1991; Hankey et al., 1991; Mead et al., 2002).
Patients presenting with events in both carotid and VB territories had the highest risk of subsequent strokes (OR 2.01, 95% CI 1.3–3.1, P = 0.02, heterogeneity P = 0.41; six studies) versus carotid events alone (OR 2.93, 95% CI 1.8–4.8, P = 0.0008, heterogeneity P = 0.11) and versus VB events alone.
Risk of fatal events
In contrast to the risk of any stroke on follow-up, there was overall agreement between the different strata for the risk of fatal stroke. Patients presenting with carotid and VB territory events had the same risk of fatal stroke (OR 0.89, 95% CI 0.7–1.3, P = 0.55, heterogeneity P = 0.64; 12 studies, 9533 patients) (Table 3). We were able to calculate case fatality of stroke in eight independent studies (Cartlidge et al., 1977; Muuronen and Kaste, 1982; Eriksson, 1985; Dennis et al., 1989; Dutch TIA Trial Study Group, 1991; Farrell et al., 1991; Hankey et al., 1991; Mead et al., 2002). There was no difference between patients with VB and carotid events (OR 0.99, 95% CI 0.7–1.4, P = 0.95, heterogeneity P = 0.02). The total number of deaths during follow-up was reported for 20 independent cohorts. There was no difference in the risk of death between patients presenting with VB and carotid events (OR 0.96, 95% CI 0.8–1.1, P = 0.57, heterogeneity P = 0.38; 10 749 patients; Table 3).
|
Risk of cardiac events
Thirteen cohorts recorded myocardial infarctions or cardiac deaths during follow-up (Table 2). There was no significant difference in risk for cardiac events in patients presenting with VB and carotid events (OR 0.85, 95% CI 0.7–1.0, P = 0.07, heterogeneity P = 0.05; 9781 patients).
Risk of recurrent TIA
The number of patients with recurrent TIA(s) was reported in 13 cohorts (Table 2). Patients presenting with VB events were more likely to have a recurrent TIA than patients with carotid events (OR 1.70, 95% CI 1.3–2.2, P = 0.00007, heterogeneity P = 0.71; 1445 patients).
|
Discussion |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionReferences |
|---|
The widely held view that VB territory TIAs and minor strokes have a better prognosis than carotid territory events was supported by some studies of stroke risk (Siekert et al., 1961
; Marshall, 1964; Baker et al., 1968; Drake and Drake, 1968; Friedman et al., 1969; Acheson, 1971; Ziegler and Hassanein, 1973; Herskovits et al., 1981a, b; Simonsen et al., 1981; Heyman et al., 1984b; Sivenius et al., 1991; Grotta et al., 1992), but not others (Acheson and Hutchinson, 1964; Baker et al., 1966; Friedman et al., 1969; Ostfeld et al., 1973; Cartlidge et al., 1977; Toole et al., 1978; Heyden, 1979; Heyman et al., 1982; Muuronen and Kaste, 1982; Wiebers et al., 1982; Candelise et al., 1986; Keith et al., 1987; Whisnant and Wiebers, 1987; Baumgartner et al., 1989; Sacco et al., 1989; Cillessen et al., 1993). However, most of these studies were small and did not have the statistical power to determine differences in prognosis reliably. We found that the relative ORs of stroke for patients with VB versus carotid events depended on whether studies had included the acute phase (i.e. whether studies enrolled the majority of patients within days after the event) and also on whether the studies were hospital- or population-based.
Our multivariate analysis suggested that the higher odds of stroke in population-based studies was accounted for by the fact that these studies were more likely to have included the acute phase than hospital-based studies. Hospital-based studies tended to be outpatient-based and did not usually include recurrent strokes that occurred after the presenting event prior to being seen in clinic. Interestingly, the only hospital-based study that found a significantly increased stroke risk in patients with VB events versus carotid events had enrolled patients very early after their event (Biller et al., 1989).
Since we compared the risk of recurrent stroke in patients with VB events with that in patients with carotid events, our findings indicate that patients with VB TIAs and minor strokes have a higher risk of stroke than patients with carotid events in the acute phase, but that this is reversed in the subacute and chronic phase. Unfortunately, we were unable to compare directly the very early risk of stroke between patients with carotid and VB events, because few studies specifically reported the very early occurrence of strokes. A high early risk of stroke recurrence in patients with posterior circulation infarction compared with carotid territory strokes was reported in a previous population-based stroke incidence study (Hankey et al., 1998), but there are very few other published data. One previous imaging study found a higher prevalence of silent infarcts in patients presenting with VB TIA or minor stroke compared with patients with carotid events (Herderschee et al., 1992), but this was only a cross-sectional observation.
Other possible explanations for the differences in stroke risk between hospital- and population-based studies are first publication and reporting bias particularly as results differed between published hospital-based studies and unpublished IPD. However, we found no evidence for this. Secondly, differences in the prevalence of important risk factors could have influenced the results, but few studies reported these data by the vascular territory of the presenting event and there were no consistent differences among the seven studies that reported sex and age by vascular territory of the presenting event (Drake and Drake, 1968; Olsson et al., 1976, 1980; Haerer et al., 1977; Simonsen et al., 1981; Heyman et al., 1984b; Ueda et al., 1987), and no differences in those studies that reported data on co-morbidity and risk factors (Olsson et al., 1976; Dyken et al., 1977; Fieschi et al., 1981; Simonsen et al., 1981; Heyman et al., 1984b). Moreover, the lack of a difference between patients with VB events and carotid events in overall mortality or in risk of coronary vascular events suggests that they had similar risk factor profiles. Thirdly, a varying degree of thoroughness on follow-up between hospital- and population-based studies might have influenced the numbers of follow-up strokes if stroke severity differed between the vascular territories. Some studies have reported a better functional outcome in patients with completed posterior circulation strokes compared with carotid strokes (Check, 1982). We were unable to reliably compare the level of disability that resulted from strokes during follow-up in patients presenting with VB events versus carotid events, because insufficient data were reported. However, we found no evidence that the risk of fatal stroke was lower in patients presenting with VB events. Moreover, case fatality due to stroke during follow-up did not differ. Similarly, although some studies have reported an overall lower mortality during follow-up for patients with VB events than for patients with carotid events (Acheson and Hutchinson, 1964; Marshall, 1964; Ziegler and Hassanein, 1973; Simonsen et al., 1981; Howard et al., 1987; Turney et al., 1984), our analysis shows that there is no difference in mortality.
Methodological issues
There are a number of methodological issues that require discussion. First, there was a wide variation in study methodology, and most studies of the studies that we included fell short of the gold standard of an inception cohort with all patients enrolled at a similar stage of their illness in a similar setting (Kernan et al., 1991). The time allowed between qualifying event and enrolment differed widely between studies (range 12 h to 1 year), and the length of follow-up varied from a few days to >10 years. The studies included ranged from the mid-1950s to the late 1990s. Absolute risks of stroke and death are likely to have diminished since the introduction of effective preventive therapies, such as anti-platelet agents, treatment of hypertension and hyper-cholesterolaemia. We therefore limited our analyses to the relative odds of recurrent events between patients with VB and carotid events within studies, and did not attempt to estimate overall absolute risks. There was no evidence in any of the studies of systematic differences between patients presenting with VB and carotid events in the timing of presenting events, the time-course of outcome events, the length of follow-up or the use of pharmacological treatments.
Secondly, we combined data on patients presenting with TIAs and minor ischaemic strokes because they have a similar underlying pathology and prognosis (Wiebers et al., 1982; Calandre and Molina, 1985; Sørensen et al., 1989; Dennis et al., 1990a; Carolei et al., 1992; Koudstaal et al., 1992), and patients with TIA frequently have appropriately localized infarcts on brain imaging (Murros et al., 1989; Kidwell et al., 1999).
Thirdly, there was considerable variation between studies in what proportion of all events were in the VB territory, ranging from 17 to 56% in population-based studies (Ostfeld et al., 1973; Wiebers et al., 1982; Keith et al., 1987), and 15 to 72% in hospital-based studies. This variation will have been due partly to differences in patient selection, and partly to variation in diagnostic criteria. Studies published after the introduction of the Ad Hoc Committee National Institute of Neurological and Communicative Disorders and Stroke (1975) diagnostic classification were more consistent with 15–35% of patients reported to have presented with VB events. However, differences in diagnostic criteria or patient selection did not appear to have influenced our results. There was no difference in the relative odds of stroke in patients presenting with VB versus carotid events between studies that used the strict diagnostic criteria and those that did not, and no correlation between the relative odds and the proportion of the study sample that presented with VB events.
Finally, some studies included patients who underwent carotid endarterectomy during follow-up. However, endarterectomy was only usually performed on a small proportion of patients with carotid events (mostly <10%) and this is unlikely to have had a major effect on the overall risk of recurrent stroke. Few studies reported patients presenting with amaurosis fugax separately from carotid territory cerebral events. It was therefore not possible to assess what impact their better prognosis had.
Conclusions
Our analyses are not necessarily helpful in deciding how best to manage individual patients with VB TIA or minor stroke. This can be very difficult, not least because of the difficulty in reliably distinguishing clinically between ischaemic events affecting the different territories within the posterior circulation (Caplan, 2000). However, our results do provide useful data to guide treatment policy for patients presenting with VB events. Despite the variations in study methodology and patient selection, our findings were remarkably consistent. Compared with patients presenting with carotid TIA or minor stroke, there is no evidence that patients with VB events have a lower risk of subsequent stroke or death. Indeed, their risk of stroke is probably higher in the acute phase. Patients with VB events require active preventive treatment.
There were no differences however, in the risk of fatal strokes, cardiac events or all cause mortality (mainly vascular), and there was a higher risk of recurrent TIAs for patients with VB events. Overall, this suggests that patients presenting with VB events are no less likely to have serious underlying vascular pathology.
|
Acknowledgements |
|---|
We wish to thank Dr S. Howard for statistical advice and Dr S. Guthikov and Mr R. Bond for assistance with analysis of data. E.F and P.M.R. are funded by the UK Medical Research Council.
|
References |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionReferences |
|---|
Acheson J. Factors affecting the natural history of "focal cerebral vascular disease". Q J Med 1971; 40: 25–46.[Web of Science][Medline]
Acheson J, Hutchinson EC. Observations on the natural history of transient cerebral ischaemia. Lancet 1964; ii: 871–4.
3 Ad Hoc Committee National Institute of Neurological and Communicative Disorders and Stroke. A classification and outline of cerebrovascular diseases. II. Stroke 1975; 6: 564–616.
Baker RN. Prospective study of transient ischemic attacks. In: Toole JF, Moossy J, Janeway R, editors. Cerebral vascular diseases. New York: Grune & Stratton; 1971. p. 166–9.
Baker RN, Schwartz WS, Rose AS. Transient ischemic strokes. A report of a study of anticoagulant therapy. Neurology 1966; 16: 841–7.
Baker RN, Ramseyer JC, Schwartz WS. Prognosis in patients with transient cerebral ischemic attacks. Neurology 1968; 18: 1157–65.
Baumgartner Ch, Zeiler K, Oder W, Binder H, Deecke L. Prognostische Faktoren für Langzeitmortalität und Schlaganfallrisiko bei Patienten mit transitorischen ischämischen Attacken. Wien Klin Wochenschr 1989; 101: 160–6.[Web of Science][Medline]
Benavente O, Eliasziw M, Streifler JY, Fox AJ, Barnett HJ, Meldrum H. Prognosis after transient monocular blindness associated with carotid-artery stenosis. New Engl J Med 2001; 345: 1084–90.
Biller J, Bruno A, Adams HP Jr, Godersky JC, Loftus CM, Mitchell VL, et al. A randomized trial of aspirin or heparin in hospitalized patients with recent transient ischemic attacks. A pilot study. Stroke 1989; 20: 441–7.
Bousser MG, Eschwege E, Haguenau M, Lefauconnier JM, Thibult N, Touboul D, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983; 14: 5–14.
Bradshaw P, McQuaid P. The syndrome of vertebrobasilar insufficiency. Q J Med 1963; 32: 279–96.[Web of Science][Medline]
Burén A, Ygge J. Treatment program and comparison between anticoagulants and platelet aggregation inhibitors after transient ischemic attack. Stroke 1981; 12: 578–80.
Calandre L, Molina JA. Short-term outcome of medically treated patients with transient ischemic attacks, reversible ischemic neurologic deficits and strokes with minimum residuum. Eur Neurol 1985; 24: 281–5.[Web of Science][Medline]
Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. New Engl J Med 1978; 299: 53–9.[Abstract]
Candelise L, Albanese V, Bono G, Brambilla L, De Zanche L, Inzitari D, et al. Prognosis of treated recent reversible ischemic attacks (RIAs): analysis of recurrence of RIAs, stroke and death according to the pathogenesis, angiographic findings, and risk factors. Pathol Biol 1982; 30: 621–4.[Web of Science]
Candelise L, Vigotti M, Fieschi C, Brambilla GL, Bono G, Conforti P, et al. Italian Multicenter Study on reversible cerebral ischemic attacks: VI—Prognostic factors and follow-up results. Stroke 1986; 17: 842–8.
Caplan LR. Posterior circulation disease. Cambridge (MA): Blackwell Science; 1996. p. 20–1.
Caplan L. Posterior circulation ischemia: then, now, and tomorrow. The Thomas Willis Lecture—2000. Stroke 2000; 31: 2011–23.
Carolei A, Candelise L, Fiorelli M, Francucci BM, Motolese M, Fieschi C. Long-term prognosis of transient ischemic attacks and reversible ischemic neurologic deficits: a hospital-based study. Cerebrovasc Dis 1992; 2: 266–72.
Cartlidge NE, Whisnant JP, Elveback LR. Carotid and vertebral-basilar transient cerebral ischemic attacks. A community study, Rochester, Minnesota. Mayo Clin Proc 1977; 52: 117–20.[Web of Science][Medline]
Check WA. Predicting outcome for stroke, TIA patients. JAMA 1982; 247: 2080.
Cillessen JPM, Kappelle LJ, van Swieten JC, Algra A, van Gijn J. Does cerebral infarction after a previous warning occur in the same vascular territory? Stroke 1993; 24: 351–4.
Coull A, Silver L, Rothwell PM. Implications of rates of non fatal acute cerebrovascular versus coronary vascular events for provision of acute services: Oxford Vascular Study (OXVASC). Cerebrovasc Dis 2003; 16(54): 1–2.
Culebras A, Kase CS, Masdeu JC, Fox AJ, Bryan RN, Grossman CB, et al. Practice guidelines for the use of imaging in transient ischemic attacks and acute stroke. A report of the Stroke Council, American Heart Association. Stroke 1997; 28: 1480–97.
Davenport RJ, Dennis MS, Warlow CP. The accuracy of Scottish Morbidity Record (SMR1) data for identifying hospitalised stroke patients. Health Bull (Edinb) 1996; 54: 402–5.
David NJ, Heyman A. Factors influencing the prognosis of cerebral thrombosis and infarction due to atherosclerosis. J Chron Dis 1960; 11: 394–404.[CrossRef][Medline]
Dennis M, Bamford J, Sandercock P, Warlow C. A comparison of risk factors and prognosis for transient ischemic attacks and minor ischemic strokes. The Oxfordshire Community Stroke Project. Stroke 1989; 20: 1494–9.
Dennis M, Bamford J, Sandercock P, Molyneux A, Warlow C. Computed tomography in patients with transient ischaemic attacks: when is a transient ischaemic attack not a transient ischaemic attack but a stroke? J Neurol 1990a; 237: 257–61.[CrossRef][Web of Science][Medline]
Dennis M, Bamford J, Sandercock P, Warlow C. Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project. Stroke 1990b; 21: 848–53.
Drake WE Jr, Drake MAL. Clinical and angiographic correlates of cerebrovascular insufficiency. Am J Med 1968; 45: 253–70.[CrossRef][Web of Science][Medline]
Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New Engl J Med 1991; 325: 1261–6.[Abstract]
Dutch TIA Trial Study Group. Predictors of major vascular events in patients with a transient ischemic attack or nondisabling stroke. Stroke 1993; 24: 527–31.
Dyken ML, Conneally M, Haerer AF, Gotshall RA, Calanchini PR, Poskanzer DC, et al. Cooperative study of hospital frequency and character of transient ischemic attacks. I. Background, organization, and clinical survey. JAMA 1977; 237: 882–6.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–34.
Eriksson S-E. Enteric-coated acetylsalicylic acid plus dipyridamol compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks. Acta Neurol Scand 1985; 71: 485–93.[Web of Science][Medline]
ESPS Group. European Stroke Prevention Study. Stroke 1990; 21: 1122–30.
Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044–54.
Fieschi C, Argentino C, Rasura M. Italian study of reversible ischemic attacks. Stroke 1981; 12: 293–5.
Friedman GD, Wilson WS, Mosier JM, Colandrea MA, Nichaman MZ. Transient ischemic attacks in a community. JAMA 1969; 210: 1428–34.
Gent M, Barnett HJ, Sackett DL, Taylor DW. A randomized trial of aspirin and sulfinpyrazone in patients with threatened stroke. Results and methodological issues. Circulation 1980; 62 (6 Pt 2): V97–105.
Grotta JC, Norris JW, Kamm B. Prevention of stroke with ticlopidine: who benefits most? TASS Baseline and Angiographic Data Subgroup. Neurology 1992; 42: 111–5.
Haerer AF, Gotshall RA, Conneally PM, Dyken ML, Poskanzer DC, Price TR, et al. Cooperative study of hospital frequency and character of transient ischemic attacks. III. Variations in treatment. JAMA 1977; 238: 142–6.
Hankey GJ, Slattery JM, Warlow CP. The prognosis of hospital-referred transient ischaemic attacks. J Neurol Neurosurg Psychiatry 1991; 54: 793–802.
Hankey GJ, Slattery JM, Warlow CP. Transient ischaemic attacks: which patients are at high (and low) risk of serious vascular events? J Neurol Neurosurg Psychiatry 1992; 55: 640–52.
Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, et al. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998; 29: 2491–500.
Herderschee D, Hijdra A, Algra A, Koudstaal PJ, Kappelle LJ, van Gijn J. Silent stroke in patients with transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. Stroke 1992; 23: 1220–4.
Herskovits E, Vazquez A, Famulari A, Smud R, Tamaroff L, Fraiman H, et al. Randomised trial of pentoxifylline versus acetylsalicylic acid plus dipyridamole in preventing transient ischaemic attacks. Lancet 1981a; i: 966–8.
Herskovits E, Vazquez A, Famulari A, Tamaroff L, Fraiman H, Gonzales AM, et al. A randomized clinical trial of pentoxifylline and antiaggregants in recent transient ischemic attacks (TIA). A one year follow-up. Ric Clin Lab 1981b; 11 Suppl 1: 257–64.
Heyden S. Spontanverlauf zerebrovaskulärer ischämischer Attacken (TIA). Aktuelle Neurol 1979; 6: 119–34.
Heyman A, Gore T, Wilkinson WE, Hurwitz BJ, Burch JG, Haynes CS, et al. TIA with benign outcome [abstract]. Stroke 1982; 13: 112.
Heyman A, Wilkinson WE, Hurwitz BJ, Haynes CS, Utley CM, Rosati RA, et al. Risk of ischemic heart disease in patients with TIA. Neurology 1984a; 34: 626–30.
Heyman A, Wilkinson WG, Hurwitz BJ, Haynes CS, Utley CM. Clinical and epidemiologic aspects of vertebrobasilar and nonfocal cerebral ischemia. In: Berguer R, Bauer RB, editors. Vertebrobasilar arterial occlusive disease. New York: Raven Press; 1984b. p. 27–36.
Howard G, Toole JF, Frye-Pierson J, Hinshelwood LC. Factors influencing the survival of 451 transient ischemic attack patients. Stroke 1987; 18: 552–7.
Keith DS, Phillips SJ, Whisnant JP, Nishimaru K, O’Fallon WM. Heparin therapy for recent transient focal cerebral ischemia. Mayo Clin Proc 1987; 62: 1101–6.[Web of Science][Medline]
Kernan WN, Feinstein AR, Brass LM. A methodological appraisal of research on prognosis after transient ischemic attacks. Stroke 1991; 22: 1108–16.
Kidwell CS, Alger JR, Di Salle F, Starkman S, Villablanca P, Bentson J, et al. Diffusion MRI in patients with transient ischemic attacks. Stroke 1999; 30: 1174–80.
Koudstaal PJ, van Gijn J, Frenken CWGM, Hijdra A, Lodder J, Vermeulen M, et al. TIA, RIND, minor stroke: a continuum, or different subgroups? Dutch TIA Study Group. J Neurol Neurosurg Psychiatry 1992; 55: 95–7.
Larsen BH, Sørensen PS, Marquardsen J. Transient ischaemic attacks in young patients: a thromboembolic or migrainous manifestation? A 10 year follow up study of 46 patients. J Neurol Neurosurg Psychiatry 1990; 53: 1029–33.
Lee TK, Lien IN, Ryu SJ, Lee KY, Hu HH, Tchen PH, et al. Secondary prevention of ischemic stroke with low dose acetylsalicylic acid. J Formos Med Assoc 1990; 89: 635–44.[Medline]
López-Gastón JI, Martín J, Errea JM, Bertol V, Pina MA. AIT. Evolutión y seguimiento. Rev Esp Neurol 1994; 9: 75–80.
Marini C, Totaro R, Carolei A. Long-term prognosis of cerebral ischemia in young adults. National Research Council Study Group on Stroke in the Young. Stroke 1999; 30: 2320–5.
Marshall J. The natural history of transient ischaemic cerebro-vascular attacks. Q J Med 1964; 33: 309–24.[Web of Science][Medline]
Marshall J, Reynolds EH. Withdrawal of anticoagulants from patients with transient ischaemic cerebrovascular attacks. Lancet 1965; i: 5–6.
Martin PJ. Vertebrobasilar ischaemia. Q J Med 1998; 91: 799–811.[Web of Science]
Matias-Guiu J, Davalos A, Pico M, Monasterio J, Vilaseca J, Codina A. Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks. Acta Neurol Scand 1987; 76: 413–21.[Web of Science][Medline]
McDowell FH, Potes J, Groch S. The natural history of internal carotid and vertebral-basilar artery occlusion. Neurology 1961; 11: 153–7.
Mead GE, Lewis SC, Wardlaw JM, Dennis MS. Comparison of risk factors in patients with transient and prolonged eye and brain ischemic syndromes. Stroke 2002; 33: 2383–90.
Mohr JP, Gautier JC, Pessin MS. Internal carotid artery disease. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, editors. Stroke. 2nd ed. New York: Churchill Livingstone; 1992. p. 311.
Murros KE, Evans GW, Toole JF, Howard G, Rose LA. Cerebral infarction in patients with transient ischemic attacks. J Neurol 1989; 236: 182–4.[CrossRef][Web of Science][Medline]
Muuronen A, Kaste M. Outcome of 314 patients with transient ischemic attacks. Stroke 1982; 13: 24–31.[Abstract]
Olsson JE, Müller R, Berneli S. Long-term anticoagulant therapy for TIAs and minor strokes with minimum residuum. Stroke 1976; 7: 444–51.
Olsson J-E, Brechter C, Bäcklund H, Krook H, Müller R, Nitelius E, et al. Anticoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks. Stroke 1980; 11: 4–9.
Omae T. Natural history of transient cerebral ischaemia as observed among the Japanese. In: Hatano S, Shigematsu I, Strasser T, editors. Hypertension and stroke control in the population. Proceedings of a WHO meeting held in Tokyo, 11–13 March 1974. Geneva: WHO; 1976. p. 284–9.
Ostfeld AM, Shekelle RB, Klawans HL. Transient ischemic attacks and risk of stroke in an elderly poor population. Stroke 1973; 4: 980–6.
Prencipe M, Culasso F, Rasura M, Anzini A, Beccia M, Cao M, et al. Long-term prognosis after a minor stroke: 10-year mortality and major stroke recurrence rates in a hospital-based cohort. Stroke 1998; 29: 126–32.
Puranen J, Laakso M, Riekkinen P, Sivenius J. Risk factors and antiplatelet therapy in TIA and stroke patients. J Neurol Sci 1998; 154: 200–4.[CrossRef][Web of Science][Medline]
Putman SF, Adams HP Jr. Usefulness of heparin in initial management of patients with recent transient ischemic attacks. Arch Neurol 1985; 42: 960–2.
Reuther R, Dorndorf W, Loew D. Behandlung transitorisch-ischämischer Attacken mit Aazetylsalizylsäure. MMW Münch Med Wochenschr 1980; 122: 795–8.[Medline]
Sacco RL, Foulkes MA, Mohr JP, Wolf PA, Hier DB, Price T. Determinants of early recurrence of cerebral infarction: The Stroke Data Bank. Stroke 1989; 20: 983–9.
Siekert RG, Millikan CH, Whisnant JP. Anticoagulant therapy in intermittent cerebrovascular insufficiency. JAMA 1961; 176: 19–22.
Simonsen N, Christiansen HD, Heltberg A, Marquardsen J, Pedersen HE, Sørensen PS. Long-term prognosis after transient ischemic attacks. Acta Neurol Scand 1981; 63: 156–68.[Web of Science][Medline]
Sivenius J, Riekkinen PJ, Smets P, Laakso M, Lowenthal A. The European Stroke Prevention Study (ESPS): results by arterial distribution. Ann Neurol 1991; 29: 596–600.[CrossRef][Web of Science][Medline]
Sørensen PS, Pedersen H, Marquardsen J, Petersson H, Heltberg A, Simonsen N, et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible ischemic attacks. Stroke 1983; 14: 15–22.
Sørensen PS, Marquardsen J, Pedersen H, Heltberg A, Munck O. Long-term prognosis and quality of life after reversible cerebral ischemic attacks. Acta Neurol Scand 1989; 79: 204–13.[Web of Science][Medline]
Sterne JAC, Bradburn MJ, Egger M. Dealing with zero cells. In: Egger M, Smith GD, Altman DG, editors. Systematic reviews in health care. Meta-analysis in context. 2nd ed. London: BMJ; 2001. p. 375–6.
Streifler JY, Eliasziw M, Benavente OR, Harbison JW, Hachinski VC, Barnett HJ, et al. The risk of stroke in patients with first-ever retinal vs hemispheric transient ischemic attacks and high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial. Arch Neurol 1995; 52: 246–9.
Toole JF, Yuson CP, Janeway R, Johnston F, Davis C, Cordell AR, et al. Transient ischemic attacks: a prospective study of 225 patients. Neurology 1978; 28: 746–53.
Tsuda Y, Kimura K, Yoneda S, Miyai M, Isaki Y, Abe H. Transient ischemic attacks: racial differences, treatment, and prognosis. Neurol Res 1983; 5: 103–17.[Medline]
Turney T, Garraway WM, Whisnant JP. The natural history of hemispheric and brainstem infarction in Rochester, Minnesota. Stroke 1984; 15: 790–4.
Ueda K, Kiyohara Y, Hasuo Y, Yanai T, Kawano H, Wada J, et al. Transient cerebral ischemic attacks in a Japanese population, Hisayama, Japan. Stroke 1987; 18: 844–8.
Whisnant JP, Wiebers DO. Clinical epidemiology of transient cerebral ischaemic attacks (TIA) in the anterior and posterior cerebral circulation. In: Sundt TM, editor. Occlusive cerebrovascular disease, diagnosis and surgical management. Philadelphia: Saunders; 1987. p. 60–5.
Whisnant JP, Matsumoto N, Elveback LR. Transient cerebral ischemic attacks in a community: Rochester, Minnesota, 1955 through 1969. Mayo Clin Proc 1973; 48: 194–8.[Web of Science][Medline]
Whisnant JP, Cartlidge NE, Elveback LR. Carotid and vertebral-basilar transient ischemic attacks: effect of anticoagulants, hypertension, and cardiac disorders on survival and stroke occurrence—a population study. Ann Neurol 1978; 3: 107–15.[CrossRef][Web of Science][Medline]
Wiebers DO, Whisnant JP, O’Fallon WM. Reversible ischemic neurologic deficit (RIND) in a community: Rochester, Minnesota, 1955–1974. Neurology 1982; 32: 459–65.
Ziegler DK, Hassanein RS. Prognosis in patients with transient ischemic attacks. Stroke 1973; 4: 666–73.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Hua, X.-F. Meng, L.-Y. Jia, C. Ling, Z.-R. Miao, F. Ling, and J.-B. Liu Color Doppler Imaging Evaluation of Proximal Vertebral Artery Stenosis Am. J. Roentgenol., November 1, 2009; 193(5): 1434 - 1438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Khan, P. Rich, A. Clifton, and H. S. Markus Noninvasive Detection of Vertebral Artery Stenosis: A Comparison of Contrast-Enhanced MR Angiography, CT Angiography, and Ultrasound Stroke, November 1, 2009; 40(11): 3499 - 3503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gulli, S. Khan, and H. S. Markus Vertebrobasilar Stenosis Predicts High Early Recurrent Stroke Risk in Posterior Circulation Stroke and TIA Stroke, August 1, 2009; 40(8): 2732 - 2737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D S Lasserson Initial management of suspected transient cerebral ischaemia and stroke in primary care: implications of recent research Postgrad. Med. J., August 1, 2009; 85(1006): 422 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Marquardt, W. Kuker, A. Chandratheva, O. Geraghty, and P. M. Rothwell Incidence and prognosis of >=50% symptomatic vertebral or basilar artery stenosis: prospective population-based study Brain, April 1, 2009; 132(4): 982 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Flossmann, J. N. Redgrave, D. Briley, and P. M. Rothwell Reliability of Clinical Diagnosis of the Symptomatic Vascular Territory in Patients With Recent Transient Ischemic Attack or Minor Stroke Stroke, September 1, 2008; 39(9): 2457 - 2460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ois, M. Gomis, A. Rodriguez-Campello, E. Cuadrado-Godia, J. Jimenez-Conde, C. Pont-Sunyer, G. Cuccurella, and J. Roquer Factors Associated With a High Risk of Recurrence in Patients With Transient Ischemic Attack or Minor Stroke Stroke, June 1, 2008; 39(6): 1717 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Khan, G C Cloud, S Kerry, and H S Markus Imaging of vertebral artery stenosis: a systematic review J. Neurol. Neurosurg. Psychiatry, November 1, 2007; 78(11): 1218 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Coward, D. J.H. McCabe, J. Ederle, R. L. Featherstone, A. Clifton, M. M. Brown, and on behalf of the CAVATAS Investigators Long-Term Outcome After Angioplasty and Stenting for Symptomatic Vertebral Artery Stenosis Compared With Medical Treatment in the Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS): A Randomized Trial Stroke, May 1, 2007; 38(5): 1526 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P M Rothwell Atherothrombosis and ischaemic stroke BMJ, February 24, 2007; 334(7590): 379 - 380. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Rothwell and S. C. Johnston Transient Ischemic Attacks: Stratifying Risk Stroke, February 1, 2006; 37(2): 320 - 322. [Full Text] [PDF]
|
|
|
|
|
|
M. Correia, M. R. Silva, R. Magalhaes, L. Guimaraes, and M. Carolina Silva Transient Ischemic Attacks in Rural and Urban Northern Portugal: Incidence and Short-Term Prognosis Stroke, January 1, 2006; 37(1): 50 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Hankey, L. J. Coward, R. L. Featherstone, and M. M. Brown Percutaneous Transluminal Angioplasty and Stenting for Vertebral Artery Stenosis Stroke, September 1, 2005; 36(9): 2047 - 2048. [Full Text] [PDF]
|
|
|
|
 |
|
 J. U. Harrer, T. Wessels, S. Poerwowidjojo, W. Moller-Hartmann, and C. Klotzsch Three-Dimensional Color-Coded Duplex Sonography for Assessment of the Vertebral Artery Origin and Vertebral Artery Stenoses J. Ultrasound Med., August 1, 2004; 23(8): 1049 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Coull and P. M. Rothwell Underestimation of the Early Risk of Recurrent Stroke: Evidence of the Need for a Standard Definition Stroke, August 1, 2004; 35(8): 1925 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Rudd and D. B. Matchar Health Policy and Outcome Research in Stroke Stroke, February 1, 2004; 35(2): 397 - 400. [Full Text] [PDF]
|
|
|
|
|
|
P A G Sandercock Should I start all my ischaemic stroke and TIA patients on a statin, an ACE inhibitor, a diuretic, and aspirin today? J. Neurol. Neurosurg. Psychiatry, November 1, 2003; 74(11): 1461 - 1464. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||